Company Encyclopedia
View More
name
IO Biotech
IOBT.US
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors.
1.898 T
IOBT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    IO Biotech Presents at Jefferies Global Healthcare Conference

    IO Biotech announced its participation in the Jefferies Global Healthcare Conference on November 18, 2025, to present updated corporate information. The company highlighted promising Phase 3 trial results for Cylembio in treating advanced melanoma, showing improved progression-free survival. Despite financial instability, clinical progress and secured financing improve future prospects. Analyst rating is Hold with a $0.39 price target. Technical sentiment is Strong Sell, with a market cap of $54.52M.

    Tip Ranks·
    US
    IOBT
    +25.13%
    Tip Ranks·
    US
    IOBT
    +25.13%

    IO Biotech’s Hold Rating Amid Financial and Regulatory Uncertainty

    Morgan Stanley analyst Michael Ulz maintains a Hold rating on IO Biotech with a $0.39 price target due to financial and regulatory uncertainties. The company awaits an FDA meeting in December for its Phase 3 trial design of Cylembio, a drug with promising but not statistically significant Phase 2 results. IO Biotech's cash reserves are limited, supporting operations only until Q1 2026. Ulz suggests a wait-and-see approach for clarity on financial and regulatory paths. Ulz is a 3-star analyst with a 2.6% average return and 43.71% success rate.

    Tip Ranks·
    US
    IOBT
    +25.13%
    Tip Ranks·
    US
    IOBT
    +25.13%

    IO Skids on Q3 Figures

    IO Biotech (NASDAQ: IOBT) reported Q3 2025 financial results and business highlights. The IOB-013 study missed statistical significance on the primary PFS endpoint but supported the mechanism of action of their cancer vaccines. The company plans to discuss the next Phase 3 study for Cylembio with the FDA in December. IOBT shares fell 2.8% to 79 cents.

    Baystreet·
    US
    IOBT
    +25.13%
    Baystreet·
    US
    IOBT
    +25.13%

    IO Biotech | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    IOBT
    +25.13%
    LB filings·
    US
    IOBT
    +25.13%

    IO Biotech, Inc. SEC 10-Q Report

    IO Biotech, Inc. released its Q3 2025 10-Q report, highlighting a decrease in operating expenses and net loss compared to 2024. The company is advancing its T-win® platform and clinical trials, despite the FDA's recommendation against a BLA submission based on current data. IO Biotech is restructuring, reducing its workforce by 50%, and focusing on new studies and ongoing trials. The report underscores progress in clinical programs and operational strategies.

    TradingView·
    US
    IOBT
    +25.13%
    TradingView·
    US
    IOBT
    +25.13%